Financial News
All
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Macro
All Sentiment
Bullish
Neutral
Bearish
3,695 articles
Meta CTO Andrew Bosworth To Lead Massive 'AI For Work' Takeover Across 78,000 Staff
Meta Platforms, Inc (NASDAQ:META) is accelerating its AI push internally while analysts see the strategy supporting long-term growth.
CTO Takes Lead...
Earnings Scheduled For March 25, 2026
Companies Reporting Before The Bell
• Chewy (NYSE:CHWY) is expected to report quarterly earnings at $0.20 per share on revenue of $3.26 billion.
•...
Earnings Scheduled For March 25, 2026
Companies Reporting Before The Bell
• Chewy (NYSE:CHWY) is expected to report quarterly earnings at $0.20 per share on revenue of $3.26 billion.
•...
Earnings Scheduled For March 25, 2026
Companies Reporting Before The Bell
• Chewy (NYSE:CHWY) is expected to report quarterly earnings at $0.20 per share on revenue of $3.26 billion.
•...
Earnings Scheduled For March 25, 2026
Companies Reporting Before The Bell
• Chewy (NYSE:CHWY) is expected to report quarterly earnings at $0.20 per share on revenue of $3.26 billion.
•...
Earnings Scheduled For March 25, 2026
Companies Reporting Before The Bell
• Chewy (NYSE:CHWY) is expected to report quarterly earnings at $0.20 per share on revenue of $3.26 billion.
•...
Earnings Scheduled For March 25, 2026
Companies Reporting Before The Bell
• Chewy (NYSE:CHWY) is expected to report quarterly earnings at $0.20 per share on revenue of $3.26 billion.
•...
Earnings Scheduled For March 25, 2026
Companies Reporting Before The Bell
• Chewy (NYSE:CHWY) is expected to report quarterly earnings at $0.20 per share on revenue of $3.26 billion.
•...
Earnings Scheduled For March 25, 2026
Companies Reporting Before The Bell
• Chewy (NYSE:CHWY) is expected to report quarterly earnings at $0.20 per share on revenue of $3.26 billion.
•...
Earnings Scheduled For March 25, 2026
Companies Reporting Before The Bell
• Chewy (NYSE:CHWY) is expected to report quarterly earnings at $0.20 per share on revenue of $3.26 billion.
•...
Earnings Scheduled For March 25, 2026
Companies Reporting Before The Bell
• Chewy (NYSE:CHWY) is expected to report quarterly earnings at $0.20 per share on revenue of $3.26 billion.
•...
Earnings Scheduled For March 25, 2026
Companies Reporting Before The Bell
• Chewy (NYSE:CHWY) is expected to report quarterly earnings at $0.20 per share on revenue of $3.26 billion.
•...
Earnings Scheduled For March 25, 2026
Companies Reporting Before The Bell
• Chewy (NYSE:CHWY) is expected to report quarterly earnings at $0.20 per share on revenue of $3.26 billion.
•...
BAE Systems and U.S. Department of War sign agreement to quadruple THAAD seeker production
FALLS CHURCH, Va. and NASHUA, N.H., March 25, 2026 /PRNewswire/ -- BAE Systems (LON: BA) has signed a landmark seven-year framework agreement with...
Lockheed Martin Answers the Nation's Call and Quadruples Precision Strike Missile Production
New agreement between Lockheed Martin and the Department of War ensures joint forces have the military advantage they need DALLAS, March 25, 2026...
HONEYWELL AEROSPACE, DEPARTMENT OF WAR SIGN GROUNDBREAKING AGREEMENT TO ACCELERATE PRODUCTION OF DEFENSE TECHNOLOGIES
Honeywell to commit $500 million for production capacity upgrades PHOENIX, March 25, 2026 /PRNewswire/ -- Honeywell (NASDAQ: HON) today announced it...
📰
Picard Medical Reports Full Year 2025 Financial Results
Revenue Growth and Continued Adoption of SynCardia Total Artificial Heart Revenue Growth and Continued Adoption of SynCardia Total Artificial Heart
📰
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support...
📰
Picard Medical Reports Full Year 2025 Financial Results
TUCSON, Ariz., March 25, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) (the "Company"), parent company of SynCardia Systems LLC, maker...
Guidehouse Secures All Six Lots on UK Government's £18B TS4 Framework
Placement across all lots reinforces Guidehouse's ability to deliver integrated strategy, design, and technology services LONDON, March 25, 2026...
Algernon Health Announces NOVASCAN NEUROIMAGING CLINICS™ as the New Brand Name for its U.S. Brain PET Scanning Centers
VANCOUVER, British Columbia, March 25, 2026 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0)...
📰
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
Novel Combination Regimen Positions Cemsidomide for Use in Earlier Lines of Therapy Novel Combination Regimen Positions Cemsidomide for Use in...
📰
Inscobee Inc. and Apimeds, Inc. Reaffirms Appointment of New Board of Directors for Apimeds Pharmaceuticals US, Inc.
Rejects Allegations of MindWave Innovations, Inc.
📰
Tilray Brands to Announce Third Quarter Fiscal Year 2026 Financial Results on April 1, 2026
NEW YORK and LEAMINGTON, Ontario, March 25, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a...
📰
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support...
📰
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM...
📰
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM...
📰
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
Terns' lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for...
📰
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
Terns' lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for...
📰
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for...
📰
AdaptHealth (AHCO) Surges 10.7%: Is This an Indication of Further Gains?
AdaptHealth (AHCO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for...
📰
AdaptHealth (AHCO) Surges 10.7%: Is This an Indication of Further Gains?
AdaptHealth (AHCO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for...
Merck Nears $6 Billion Deal To Buy Terns Pharma: Report
Merck & Co. Inc. (NYSE:MRK) is nearing an all-cash deal to acquire Terns Pharmaceuticals, Inc. (NASDAQ:TERN) for roughly $6 billion, aiming to...
Merck Nears $6 Billion Deal To Buy Terns Pharma: Report
Merck & Co. Inc. (NYSE:MRK) is nearing an all-cash deal to acquire Terns Pharmaceuticals, Inc. (NASDAQ:TERN) for roughly $6 billion, aiming to...
Merck Nears $6 Billion Deal To Buy Terns Pharma: Report
Merck & Co. Inc. (NYSE:MRK) is nearing an all-cash deal to acquire Terns Pharmaceuticals, Inc. (NASDAQ:TERN) for roughly $6 billion, aiming to...
📰
3 Top-Ranked Healthcare Mutual Funds Set for Solid Growth
We share with you three top-ranked healthcare mutual funds. Each has a Zacks Mutual Fund Rank #1 (Strong Buy).
📰
So-Young Reports Unaudited Fourth Quarter and Fiscal Year 2025 Financial Results
<p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml"...